Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
R&D
Page 53
R&D
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
FDA orphan drug and rare pediatric disease designations granted to Arbor Biotechnologies’ primary hyperoxaluria type 1 treatment
Relmada Therapeutics acquires potential Tourette syndrome therapy from Asarina Pharma
Vanda Pharmaceuticals and AnaptysBio announce global license agreement for Generalized Pustular Psoriasis treatment
UNION and Innovent collaborate on next-gen PDE4 inhibitor for inflammatory dermatology...
30th September 2021
Syndax and Incyte to develop axatilimab for fibrotic diseases
29th September 2021
New data on amivantamab in combination with lazertinib show early activity...
28th September 2021
Janssen presents results from Phase 1b/2 NORSE study in patients with...
28th September 2021
European study highlights the utility of Beckman Coulter’s MDW biomarker for...
24th September 2021
Eye care collaboration for AbbVie and REGENXBIO
15th September 2021
Exscientia and Gates Foundation to develop therapeutics against coronavirus and pandemic...
13th September 2021
Adaptimmune and Genentech partner on cancer-targeted allogeneic T-cell therapies
13th September 2021
Real-world evidence demonstrates significant difference in fracture risk reduction for osteoporosis...
28th August 2021
Lilly and Lycia to develop novel lysosomal targeting chimera degraders
27th August 2021
1
...
52
53
54
Page 53 of 54
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...